Adverse Impact of DNA Methylation Regulatory Gene Mutations on the Prognosis of AML Patients in the 2017 ELN Favorable Risk Group, Particularly Those Defined by NPM1 Mutation.

摘要: The 2017 ELN risk stratification has been widely adopted, but some studies have suggested the outcomes are heterogenous within groups and may be affected by other co-existing genetic mutations. This study evaluated impact of DNA methylation regulatory gene (TET2, IDH1/2, DNMT3A, SETBP1) mutations (DMRGM) NGS in outcome AML patients each group. A total 114 were analyzed with a median follow-up 12 months. Overall, 30.7% (35/114) had DMRGM. DMRGM status no on CR rate OS, however, was significantly shorter compared to those without (median OS: vs. 33 months, p = 0.0053). Multivariate analysis showed an independent unfavorable factor for OS (HR: 2.704, 95% CI: 1.451-5.041, 0.0017). adverse only observed favorable group (7 months not reached, 0.0001), intermediate or Among (n 16), occurred predominantly cases mutated NPM1 (15/16, 93.8%). Our results suggest that adversely patients, particularly NPM1. Further warranted confirm our observations.